Prednisolone reduces recurrent wheezing after first rhinovirus wheeze: a 7-year follow-up.

ABSTRACT:

Background

To better understand the role of human rhinovirus-associated wheeze as a risk factor for childhood recurrent wheezing, a cohort of young children experiencing their first wheezing episode was followed until school age.

Methods

All 111 hospitalized wheezing children (median age, 12 months) were initially participated in a randomized, double-blind, placebo-controlled, parallel trial on the efficacy of oral prednisolone. In this 7-yr follow-up, risk factors for recurrent wheezing were analysed, and then, the efficacy of prednisolone was evaluated overall and in pre-specified subgroups post-hoc. The main outcome was time to recurrent wheezing.

Results

The strongest independent risk factor for recurrent wheezing was rhinovirus detection (hazard ratio 3.54; 95% c

SUBMITTER: Lukkarinen M 

PROVIDER: S-EPMC7167822 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature